Elanco Animal Health Incorporated (ELAN) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Elanco Animal Health Incorporated (NYSE: ELAN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $24.57 (+1.95% 1D, market cap $12.04B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, ELAN ranks #357 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELAN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 55.0%, and ROIC of -2.5%. By comparison, SMMT (Summit Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $11.84B) and RDY (Dr. Reddy's Laboratories Ltd) posts a C grade (64/100 RQD, P/E 32.8x, ROIC 9.9%, cap $11.79B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).
Per ELAN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001739104), Elanco Animal Health Incorporated generated $4.71B in revenue (+6.2% YoY), -$232.0M in net income, and $284.0M in free cash flow against $13.36B in total assets and $3.06B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC Form 4 / 13F Thermometer: 60% Net Buy • Cannibal Buyback (-1.24% YoY Shares)
Altman Z-Score 1.24 (DISTRESS RISK (<1.8)) • Piotroski F-Score 7/9
Macro rate sensitivity & RSI-14 (63.3) create a -15 pt regime headwind
While ELAN currently carries a cautious 45/100 (D) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.03) and Max Pain ($25.80) forces dealer call-delta covering toward $29.38.
Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.24% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Elanco Animal Health Incorporated (ELAN) advanced +1.95% to $24.57, trading at 60% of its 52-week range ($19.4 – $27.98). Stretched risk/reward at current multiples (-3% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.
VTRS, RVTY, ELAN and VCYT have earnings beat signals ahead of Q3 results. Can drug launches, lab spending and cancer tests overcome margin pressures?
APA Corporation is set to report Q3 2026 results, with higher oil prices potentially boosting revenues, while rising operating expenses could pressure earnings.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ELAN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ELAN. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Elanco Animal Health Incorporated (ELAN) ranks #357 by composite RQD confidence (45/100, grade D) and #91 by equity capitalization ($12.04B). Within this direct 5-issuer industry benchmark cohort, BMRN leads on earnings valuation at 31.9x trailing P/E, while RDY leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. BMRN currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with ELAN at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ELAN
ACTIVE
Elanco Animal Health Incorporated | D | 45/100 | — | 55.0% | -2.5% | +1.95% | $12.04B | Benchmark Subject |
| SMMT Summit Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | +6.76% | $11.84B | /smmt-vs-elan → |
| RDY Dr. Reddy's Laboratories Ltd | C | 64/100 | 32.8x | — | 9.9% | +1.20% | $11.79B | /rdy-vs-elan → |
| BMRN BioMarin Pharmaceutical Inc. | B | 74/100 | 31.9x | 77.7% | 6.0% | -3.10% | $11.12B | /bmrn-vs-elan → |
| JAZZ Jazz Pharmaceuticals plc (Ireland) | D | 49/100 | — | — | -4.7% | +7.14% | $13.92B | /jazz-vs-elan → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Elanco Animal Health Incorporated (ELAN) reported GAAP revenue of $4.71B (+6.2% vs. FY2024 revenue of $4.44B , and +6.7% cumulative change since FY2023) , GAAP net income of -$232.0M, operating cash flow of $560.0M, and free cash flow of $284.0M (-27.9% YoY). On the balance sheet, ELAN closed FY2025 with $13.36B in total assets against $3.06B in total debt (Altman Z-Score: 1.24, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $4.71B | -$232.0M | $560.0M | $284.0M | $13.36B | $3.06B |
| FY2024 (FY) | 2024-12-31 | $4.44B | $338.0M | $541.0M | $394.0M | $12.61B | $4.28B |
| FY2023 (FY) | 2023-12-31 | $4.42B | -$1.23B | $271.0M | $72.2M | $6.39B | $1.49B |
As of 2026-11-03, Elanco Animal Health Incorporated (NYSE: ELAN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $24.57 (+1.95% 1D, market cap $12.04B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, ELAN ranks #357 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELAN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 55.0%, and ROIC of -2.5%. By comparison, SMMT (Summit Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $11.84B) and RDY (Dr. Reddy's Laboratories Ltd) posts a C grade (64/100 RQD, P/E 32.8x, ROIC 9.9%, cap $11.79B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).
Per ELAN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001739104), Elanco Animal Health Incorporated generated $4.71B in revenue (+6.2% YoY), -$232.0M in net income, and $284.0M in free cash flow against $13.36B in total assets and $3.06B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
ELAN last traded at $24.57 (+1.95% on volume of 6,460,538 shares), positioning the stock +6.69% above its 50-day simple moving average ($23.03) and +3.37% above its 200-day simple moving average ($23.77). Across its 52-week range of $19.40 to $27.98, ELAN sits at the 60.3% percentile with a 14-day RSI of 63.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.1% ($23.07 to $26.07).
Elanco Animal Health Incorporated (ELAN) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $24.57 (+1.95% 1D, market capitalization $12.04B).
Elanco Animal Health Incorporated is a NYSE-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. The profile identifies the company as operating in animal health. The company carries a market capitalization of $11.6B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Elanco Animal Health Incorporated (ELAN) reported $4.71B in annual revenue (up from $4.44B in FY2024, +6.2% YoY) and -$232.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($4.42B revenue, -$1.23B net income) through FY2025, ELAN scaled operating cash flow to $560.0M and free cash flow to $284.0M, backed by $13.36B in total assets against $3.06B in total debt.
Investors should note that the absence of mapped links is a data gap, not evidence of an absence of dependencies.
Real-time company headlines, analyst actions, and sector developments for Elanco Animal Health Incorporated (ELAN) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.
Long ELAN at $23.06 targeting $29.06. Forward P/E of 20 and a Piotroski F-Score of 7/9 suggest the market expects and the balance sheet can support an earnings and cash-flow recovery from negative trailing results.. Institutional whale score is 9/20 and the risk/reward vs. the $19.40 52-week low is skewed heavily in favor of bulls.
Both sides have a point here — ELAN's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Sitting on the sidelines or leaning short ELAN above $23.06. Negative ROIC of -2.5%, an Altman Z of 1.24, and the lowest pillar score of 5/20 on macro regime fit point to weak economics and limited sector tailwind.. Until Fundamental Cash Engine (9/20) and FCF yield (2.45%) inflect higher, upside is capped near $27.98.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: